Michael Ploug

List of Publications by Year
in descending order

131 papers	6,425 citations	41344 49 h-index	74163 75 g-index
134 all docs	134 docs citations	134 times ranked	4715 citing authors

#	Article	IF	Citations
1	ANGPTL4: a new mode in the regulation of intravascular lipolysis. Current Opinion in Lipidology, 2022, 33, 112-119.	2.7	9
2	Electrostatic sheathing of lipoprotein lipase is essential for its movement across capillary endothelial cells. Journal of Clinical Investigation, 2022, 132, .	8.2	13
3	Smallâ€Molecule Inhibition of the uPARâ€‰â‹…â€‰uPA Interaction by Conformational Selection. ChemMedChem, 2021, 16, 377-387.	3.2	9
4	Disorder in a two-domain neuronal Ca2+-binding protein regulates domain stability and dynamics using ligand mimicry. Cellular and Molecular Life Sciences, 2021, 78, 2263-2278.	5.4	4
5	The intrinsic instability of the hydrolase domain of lipoprotein lipase facilitates its inactivation by ANGPTL4-catalyzed unfolding. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	29
6	GPIHBP1 and ANGPTL4 Utilize Protein Disorder to Orchestrate Order in Plasma Triglyceride Metabolism and Regulate Compartmentalization of LPL Activity. Frontiers in Cell and Developmental Biology, 2021, 9, 702508.	3.7	22
7	The Importance of Lipoprotein Lipase Regulation in Atherosclerosis. Biomedicines, 2021, 9, 782.	3.2	33
8	Targeting the Urokinase-Type Plasminogen Activator Receptor (uPAR) in Human Diseases With a View to Non-invasive Imaging and Therapeutic Intervention. Frontiers in Cell and Developmental Biology, 2021, 9, 732015.	3.7	16
9	IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts. Theranostics, 2021, 11, 7159-7174.	10.0	11
10	ANGPTL4 sensitizes lipoprotein lipase to PCSK3 cleavage by catalyzing its unfolding. Journal of Lipid Research, 2021, 62, 100071.	4.2	9
11	The Urokinase Receptor (uPAR) as a â€œTrojan Horseâ€•in Targeted Cancer Therapy: Challenges and Opportunities. Cancers, 2021, 13, 5376.	3.7	24
12	Expression and one-step purification of active LPL contemplated by biophysical considerations. Journal of Lipid Research, 2021, 62, 100149.	4.2	7
13	Optimization and Evaluation of Al18F Labeling Using a NOTAâ€”or RESCA1-Conjugated AE105 Peptide Antagonist of uPAR. Frontiers in Nuclear Medicine, 2021, 1, .	1.2	2
14	Peptide Disc Mediated Control of Membrane Protein Orientation in Supported Lipid Bilayers for Surface-Sensitive Investigations. Analytical Chemistry, 2020, 92, 1081-1088.	6.5	14
15	Chylomicronemia From GPIHBP1 Autoantibodies Successfully Treated With Rituximab: A Case Report. Annals of Internal Medicine, 2020, 173, 764-765.	3.9	11
16	The structural basis for monoclonal antibody 5D2 binding to the tryptophan-rich loop of lipoprotein lipase. Journal of Lipid Research, 2020, 61, 1347-1359.	4.2	11
17	Chylomicronemia from GPIHBP1 autoantibodies. Journal of Lipid Research, 2020, 61, 1365-1376.	4.2	21
18	ANGPTL4 inactivates lipoprotein lipase by catalyzing the irreversible unfolding of LPL's hydrolase domain. Journal of Lipid Research, 2020, 61, 1253.	4.2	16

#	Article	IF	Citations
19	Crystal Structures of Human C4.4A Reveal the Unique Association of Ly6/uPAR/Î±-neurotoxin Domain. International Journal of Biological Sciences, 2020, 16, 981-993.	6.4	4
20	Helicobacter pylori Colonization Drives Urokinase Receptor (uPAR) Expression in Murine Gastric Epithelium During Early Pathogenesis. Microorganisms, 2020, 8, 1019.	3.6	5
21	Efficient refolding and reconstitution of tissue factor into nanodiscs facilitates structural investigation of a multicomponent system on a lipid bilayer. Biochimica Et Biophysica Acta - Biomembranes, 2020, 1862, 183214.	2.6	3
22	Unfolding of monomeric lipoprotein lipase by ANGPTL4: Insight into the regulation of plasma triglyceride metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 4337-4346.	7.1	56
23	Intermittent chylomicronemia caused by intermittent GPIHBP1 autoantibodies. Journal of Clinical Lipidology, 2020, 14, 197-200.	1.5	13
24	Determination of Binding Kinetics of Intrinsically Disordered Proteins by Surface Plasmon Resonance. Methods in Molecular Biology, 2020, 2141, 611-627.	0.9	8
25	GPIHBP1 and Lipoprotein Lipase, Partners in Plasma Triglyceride Metabolism. Cell Metabolism, 2019, 30, 51-65.	16.2	86
26	On the mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity. Journal of Lipid Research, 2019, 60, 783-793.	4.2	92
27	Origin and diversification of the plasminogen activation system among chordates. BMC Evolutionary Biology, 2019, 19, 27.	3.2	31
28	The PCNA interaction motifs revisited: thinking outside the PIP-box. Cellular and Molecular Life Sciences, 2019, 76, 4923-4943.	5.4	77
29	Evolution and Medical Significance of LU Domainâ˜Containing Proteins. International Journal of Molecular Sciences, 2019, 20, 2760.	4.1	29
30	Crystal structure of the unoccupied murine urokinaseâ€type plasminogen activator receptor (<scp>uPAR</scp>) reveals a tightly packed DIIâ€“DIII unit. FEBS Letters, 2019, 593, 1236-1247.	2.8	4
31	Did evolution create a flexible ligand-binding cavity in the urokinase receptor through deletion of a plesiotypic disulfide bond?. Journal of Biological Chemistry, 2019, 294, 7403-7418.	3.4	11
32	Lipoprotein lipase is active as a monomer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 6319-6328.	7.1	60
33	GPIHBP1 autoantibody syndrome during interferon Î²1a treatment. Journal of Clinical Lipidology, 2019, 13, 62-69.	1.5	15
34	Structure of the lipoprotein lipaseâ€“GPIHBP1 complex that mediates plasma triglyceride hydrolysis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1723-1732.	7.1	67
35	Gene Expression and Function of the Cellular Receptor for u-PA (u-PAR). , 2019, , 30-42.		0
36	NanoSIMS Analysis of Intravascular Lipolysis and Lipid Movement across Capillaries and into Cardiomyocytes. Cell Metabolism, 2018, 27, 1055-1066.e3.	16.2	54

#	Article	IF	Citations
37	An enzyme-linked immunosorbent assay for measuring GPIHBP1 levels in human plasma orÂserum. Journal of Clinical Lipidology, 2018, 12, 203-210.e1.	1.5	15
38	A disordered acidic domain in GPIHBP1 harboring a sulfated tyrosine regulates lipoprotein lipase. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6020-E6029.	7.1	51
39	GPIHBP1 autoantibodies in a patient with unexplained chylomicronemia. Journal of Clinical Lipidology, 2017, 11, 964-971.	1.5	25
40	Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia. New England Journal of Medicine, 2017, 376, 1647-1658.	27.0	112
41	Expression and crystallographic studies of the D1D2 domains of C4.4A, a homologous protein to the urokinase receptor. Acta Crystallographica Section F, Structural Biology Communications, 2017, 73, 486-490.	0.8	1
42	Mobility of â€œHSPG-boundâ€•LPL explains how LPL is able to reach GPIHBP1 on capillaries. Journal of Lipid Research, 2017, 58, 216-225.	4.2	33
43	Monoclonal antibodies that bind to the Ly6 domain of GPIHBP1 abolish the binding of LPL. Journal of Lipid Research, 2017, 58, 208-215.	4.2	15
44	Expression of C4.4A in an In Vitro Human Tissue-Engineered Skin Model. BioMed Research International, 2017, 2017, 1-9.	1.9	3
45	Peptide-Based Optical uPAR Imaging for Surgery: In Vivo Testing of ICG-Glu-Glu-AE105. PLoS ONE, 2016, 11, e0147428.	2.5	35
46	Tissue Inhibitor of Metalloproteinase-1 Is Confined to Tumor-Associated Myofibroblasts and Is Increased With Progression in Gastric Adenocarcinoma. Journal of Histochemistry and Cytochemistry, 2016, 64, 483-494.	2.5	28
47	GPIHBP1 and Plasma Triglyceride Metabolism. Trends in Endocrinology and Metabolism, 2016, 27, 455-469.	7.1	67
48	An LPLâ€“specific monoclonal antibody, 88B8, that abolishes the binding of LPL to GPIHBP1. Journal of Lipid Research, 2016, 57, 1889-1898.	4.2	10
49	C4.4A gene ablation is compatible with normal epidermal development and causes modest overt phenotypes. Scientific Reports, 2016, 6, 25833.	3.3	10
50	Urokinase receptor cleavage correlates with tumor volume in a transgenic mouse model of breast cancer. Molecular Carcinogenesis, 2016, 55, 717-731.	2.7	6
51	The acidic domain of the endothelial membrane protein GPIHBP1 stabilizes lipoprotein lipase activity by preventing unfolding of its catalytic domain. ELife, 2016, 5, e12095.	6.0	74
52	The angiopoietin-like protein ANGPTL4 catalyzes unfolding of the hydrolase domain in lipoprotein lipase and the endothelial membrane protein GPIHBP1 counteracts this unfolding. ELife, 2016, 5, .	6.0	78
53	Protein-Binding RNA Aptamers Affect Molecular Interactions Distantly from Their Binding Sites. PLoS ONE, 2015, 10, e0119207.	2.5	19
54	First-in-human uPAR PET: Imaging of Cancer Aggressiveness. Theranostics, 2015, 5, 1303-1316.	10.0	92

#	Article	IF	Citations
55	Stabilizing a Flexible Interdomain Hinge Region Harboring the SMB Binding Site Drives uPAR into Its Closed Conformation. Journal of Molecular Biology, 2015, 427, 1389-1403.	4.2	25
56	GPIHBP1 Missense Mutations Often Cause Multimerization of GPIHBP1 and Thereby Prevent Lipoprotein Lipase Binding. Circulation Research, 2015, 116, 624-632.	4.5	50
57	Expression of the Ly6/uPAR-Domain Proteins C4.4A and Haldisin in Non-Invasive and Invasive Skin Lesions. Journal of Histochemistry and Cytochemistry, 2015, 63, 142-154.	2.5	12
58	Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography. Data in Brief, 2015, 5, 107-113.	1.0	13
59	Administration of Recombinant Soluble Urokinase Receptor Per Se Is Not Sufficient to Induce Podocyte Alterations and Proteinuria in Mice. Journal of the American Society of Nephrology: JASN, 2014, 25, 1662-1668.	6.1	67
60	C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma. World Journal of Clinical Oncology, 2014, 5, 621.	2.3	8
61	Multimerization of Glycosylphosphatidylinositol-anchored High Density Lipoprotein-binding Protein 1 (GPIHBP1) and Familial Chylomicronemia from a Serine-to-Cysteine Substitution in GPIHBP1 Ly6 Domain. Journal of Biological Chemistry, 2014, 289, 19491-19499.	3.4	45
62	uPAR Targeted Radionuclide Therapy with ¹⁷⁷Lu-DOTA-AE105 Inhibits Dissemination of Metastatic Prostate Cancer. Molecular Pharmaceutics, 2014, 11, 2796-2806.	4.6	34
63	Electrochemical Reduction of Disulfide-Containing Proteins for Hydrogen/Deuterium Exchange Monitored by Mass Spectrometry. Analytical Chemistry, 2014, 86, 340-345.	6.5	51
64	Tousled-like kinases phosphorylate Asf1 to promote histone supply during DNA replication. Nature Communications, 2014, 5, 3394.	12.8	54
65	Targeting of peptide conjugated magnetic nanoparticles to urokinase plasminogen activator receptor (uPAR) expressing cells. Nanoscale, 2013, 5, 8192.	5.6	28
66	Ly6/uPAR-Related Protein C4.4A as a Marker of Solid Growth Pattern and Poor Prognosis in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2013, 8, 152-160.	1.1	21
67	The Urokinase Receptor Homolog Haldisin Is a Novel Differentiation Marker of Stratum Granulosum in Squamous Epithelia. Journal of Histochemistry and Cytochemistry, 2013, 61, 802-813.	2.5	19
68	Structure-Driven Design of Radionuclide Tracers for Non-Invasive Imaging of uPAR and Targeted Radiotherapy. The Tale of a Synthetic Peptide Antagonist. Theranostics, 2013, 3, 467-476.	10.0	28
69	Improved PET Imaging of uPAR Expression Using new 64Cu-labeled Cross-Bridged Peptide Ligands: Comparative in vitro and in vivo Studies. Theranostics, 2013, 3, 618-632.	10.0	50
70	Quantitative PET of Human Urokinase-Type Plasminogen Activator Receptor with ⁶⁴Cu-DOTA-AE105: Implications for Visualizing Cancer Invasion. Journal of Nuclear Medicine, 2012, 53, 138-145.	5.0	73
71	Targeting Tumor Cell Invasion and Dissemination In Vivo by an Aptamer That Inhibits Urokinase-type Plasminogen Activator through a Novel Multifunctional Mechanism. Molecular Cancer Research, 2012, 10, 1532-1543.	3.4	15
72	A Flexible Multidomain Structure Drives the Function of the Urokinase-type Plasminogen Activator Receptor (uPAR)*. Journal of Biological Chemistry, 2012, 287, 34304-34315.	3.4	43

#	Article	IF	Citations
73	Urokinase-type Plasminogen Activator-like Proteases in Teleosts Lack Genuine Receptor-binding Epidermal Growth Factor-like Domains. Journal of Biological Chemistry, 2012, 287, 27526-27536.	3.4	8
74	68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers. Nuclear Medicine and Biology, 2012, 39, 560-569.	0.6	51
75	Crystal Structure of the Urokinase Receptor in a Ligand-Free Form. Journal of Molecular Biology, 2012, 416, 629-641.	4.2	42
76	Hydrogen/Deuterium Exchange Mass Spectrometry Reveals Specific Changes in the Local Flexibility of Plasminogen Activator Inhibitor 1 upon Binding to the Somatomedin B Domain of Vitronectin. Biochemistry, 2012, 51, 8256-8266.	2.5	29
77	New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts. Nuclear Medicine and Biology, 2012, 39, 962-969.	0.6	36
78	Expression of C4.4A in precursor lesions of pulmonary adenocarcinoma and squamous cell carcinoma. International Journal of Cancer, 2012, 130, 2734-2739.	5.1	15
79	Plasmodium ookinetes coopt mammalian plasminogen to invade the mosquito midgut. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17153-17158.	7.1	109
80	Mimicry of the Regulatory Role of Urokinase in Lamellipodia Formation by Introduction of a Non-native Interdomain Disulfide Bond in Its Receptor. Journal of Biological Chemistry, 2011, 286, 43515-43526.	3.4	28
81	Conformational Regulation of Urokinase Receptor Function. Journal of Biological Chemistry, 2011, 286, 33544-33556.	3.4	51
82	Expression of C4.4A, a Structural uPAR Homolog, Reflects Squamous Epithelial Differentiation in the Adult Mouse and during Embryogenesis. Journal of Histochemistry and Cytochemistry, 2011, 59, 188-201.	2.5	18
83	Abstract 5280: PET imaging of proteolysis: Evaluation of 68Ga-DOTA and 68Ga-NODAGA chelates of an uPAR-specific peptide in a human glioblastoma xenograft model. , 2011, , .		0
84	Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation. Blood, 2010, 116, 1593-1603.	1.4	78
85	Structure-based Engineering of Species Selectivity in the Interaction between Urokinase and Its Receptor. Journal of Biological Chemistry, 2010, 285, 10982-10992.	3.4	68
86	Neutralisation of uPA with a Monoclonal Antibody Reduces Plasmin Formation and Delays Skin Wound Healing in tPA-Deficient Mice. PLoS ONE, 2010, 5, e12746.	2.5	25
87	Abstract 5237: Non-invasive detection of urokinase-type plasminogen activator receptor (uPAR) expression in four human cancer xenograft mouse models using microPET/CT. , 2010, , .		0
88	Interactions of Plasminogen Activator Inhibitor-1 with Vitronectin Involve an Extensive Binding Surface and Induce Mutual Conformational Rearrangements. Biochemistry, 2009, 48, 1723-1735.	2.5	20
89	Specific recognition of the C-terminal end of Aî²42 by a high affinity monoclonal antibody. Molecular Immunology, 2009, 46, 2267-2273.	2.2	9
90	Altered expression of the urokinase receptor homologue, C4.4A, in invasive areas of human esophageal squamous cell carcinoma. International Journal of Cancer, 2008, 122, 734-741.	5.1	35

#	Article	IF	Citations
91	Hydrogen atom scrambling in selectively labeled anionic peptides upon collisional activation by MALDI tandem time-of-flight mass spectrometry. Journal of the American Society for Mass Spectrometry, 2008, 19, 1719-1725.	2.8	27
92	Imaging of Urokinase-Type Plasminogen Activator Receptor Expression Using a 64Cu-Labeled Linear Peptide Antagonist by microPET. Clinical Cancer Research, 2008, 14, 4758-4766.	7.0	73
93	A Composite Role of Vitronectin and Urokinase in the Modulation of Cell Morphology upon Expression of the Urokinase Receptor. Journal of Biological Chemistry, 2008, 283, 15217-15223.	3.4	26
94	Structure and ligand interactions of the urokinase receptor (uPAR). Frontiers in Bioscience - Landmark, 2008, Volume, 5441.	3.0	57
95	17 Identification of potential target sites on the urokinase-receptor for use in antagonist-based anti-cancer therapy. Apmis, 2008, 116, 425-426.	2.0	0
96	Mapping of the Vitronectin-binding Site on the Urokinase Receptor. Journal of Biological Chemistry, 2007, 282, 13561-13572.	3.4	88
97	One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry. Protein Expression and Purification, 2007, 52, 286-296.	1.3	27
98	A new tagging system for production of recombinant proteins in Drosophila S2 cells using the third domain of the urokinase receptor. Protein Expression and Purification, 2007, 52, 384-394.	1.3	34
99	Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer. Lung Cancer, 2007, 58, 260-266.	2.0	37
100	Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: Inhibitory effects on receptormediated uPA activity in vitro and in vivo. Thrombosis and Haemostasis, 2007, 97, 1013-1022.	3.4	26
101	Solution structure of recombinant somatomedin B domain from vitronectin produced in Pichia pastoris. Protein Science, 2007, 16, 1934-1945.	7.6	32
102	Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo. Thrombosis and Haemostasis, 2007, 97, 1013-22.	3.4	13
103	Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice. EMBO Journal, 2006, 25, 2686-2697.	7.8	120
104	Characterization of the Functional Epitope on the Urokinase Receptor. Journal of Biological Chemistry, 2006, 281, 19260-19272.	3.4	78
105	A Region in Urokinase Plasminogen Receptor Domain III Controlling a Functional Association with Î±5Î²1 Integrin and Tumor Growth. Journal of Biological Chemistry, 2006, 281, 14852-14863.	3.4	110
106	Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO Journal, 2005, 24, 1655-1663.	7.8	213
107	Plasminogen activation and cancer. Thrombosis and Haemostasis, 2005, 93, 676-681.	3.4	398
108	Collisional Activation by MALDI Tandem Time-of-flight Mass Spectrometry Induces Intramolecular Migration of Amide Hydrogens in Protonated Peptides. Molecular and Cellular Proteomics, 2005, 4, 1910-1919.	3.8	36

#	Article	IF	Citations
109	Intramolecular Migration of Amide Hydrogens in Protonated Peptides upon Collisional Activation. Journal of the American Chemical Society, 2005, 127, 2785-2793.	13.7	161
110	Specific Immunoassays for Detection of Intact and Cleaved Forms of the Urokinase Receptor. Clinical Chemistry, 2004, 50, 2059-2068.	3.2	60
111	Dynamics of Urokinase Receptor Interaction with Peptide Antagonists Studied by Amide Hydrogen Exchange and Mass Spectrometryâ€. Biochemistry, 2004, 43, 15044-15057.	2.5	54
112	Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites. Protein Expression and Purification, 2004, 34, 284-295.	1.3	56
113	Structural analysis and tissue localization of human C4.4A: a protein homologue of the urokinase receptor. Biochemical Journal, 2004, 380, 845-857.	3.7	58
114	The Urokinase Receptor as a Potential Target in Cancer Therapy. Current Pharmaceutical Design, 2004, 10, 2359-2376.	1.9	110
115	Structure-Function Relationships in the Interaction Between the Urokinase- Type Plasminogen Activator and Its Receptor. Current Pharmaceutical Design, 2003, 9, 1499-1528.	1.9	153
116	Peptide-Derived Antagonists of the Urokinase Receptor. Affinity Maturation by Combinatorial Chemistry, Identification of Functional Epitopes, and Inhibitory Effect on Cancer Cell Intravasationâ€. Biochemistry, 2001, 40, 12157-12168.	2.5	170
117	The Murine Receptor for Urokinase-Type Plasminogen Activator Is Primarily Expressed in Tissues Actively Undergoing Remodeling. Journal of Histochemistry and Cytochemistry, 2001, 49, 237-246.	2.5	106
118	Plasminogen-Independent Initiation of the Pro-urokinase Activation Cascade in Vivo. Activation of Pro-urokinase by Glandular Kallikrein (mGK-6) in Plasminogen-Deficient Mice. Biochemistry, 2000, 39, 508-515.	2.5	44
119	Mapping Part of the Functional Epitope for Ligand Binding on the Receptor for Urokinase-type Plasminogen Activator by Site-directed Mutagenesis. Journal of Biological Chemistry, 1999, 274, 37995-38003.	3.4	67
120	Photoaffinity Labeling of the Human Receptor for Urokinase-Type Plasminogen Activator Using a Decapeptide Antagonist. Evidence for a Composite Ligand-Binding Site and a Short Interdomain Separation. Biochemistry, 1998, 37, 3612-3622.	2.5	78
121	Identification of Specific Sites Involved in Ligand Binding by Photoaffinity Labeling of the Receptor for the Urokinase-Type Plasminogen Activator. Residues Located at Equivalent Positions in uPAR Domains I and III Participate in the Assembly of a Composite Ligand-Binding Site. Biochemistry, 1998, 37, 16494-16505.	2.5	58
122	Glycosylation Profile of a Recombinant Urokinase-type Plasminogen Activator Receptor Expressed in Chinese Hamster Ovary Cells. Journal of Biological Chemistry, 1998, 273, 13933-13943.	3.4	62
123	The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Letters, 1997, 420, 79-85.	2.8	131
124	Chemical Modification of the Urokinase-Type Plasminogen Activator and Its Receptor Using Tetranitromethane. Evidence for the Involvement of Specific Tyrosine Residues in Both Molecules during Receptor-Ligand Interaction. Biochemistry, 1995, 34, 12524-12534.	2.5	65
125	Structure-function relationships in the receptor for urokinase-type plasminogen activator Comparison to other members of the Ly-6 family and snake venom Î±-neurotoxins. FEBS Letters, 1994, 349, 163-168.	2.8	231
126	Ligand Interaction between Urokinase-Type Plasminogen Activator and Its Receptor Probed with 8-Anilino-1-naphthalenesulfonate. Evidence for a Hydrophobic Binding Site Exposed Only on the Intact Receptor. Biochemistry, 1994, 33, 8991-8997.	2.5	113

#	Article	IF	Citations
127	[13] Cellular receptor for urokinase-type plasminogen activator: Protein structure. Methods in Enzymology, 1993, 223, 207-222.	1.0	33
128	Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator. FEBS Journal, 1992, 205, 451-458.	0.2	57
129	A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria. FEBS Journal, 1992, 208, 397-404.	0.2	66
130	Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. FEBS Letters, 1991, 288, 233-236.	2.8	177
131	Protein Structure and Membrane Anchorage of the Cellular Receptor for Urokinase-Type Plasminogen Activator. Seminars in Thrombosis and Hemostasis, 1991, 17, 183-193.	2.7	111